Pancreatic Stone Protein as an Early Predictor of Adverse Events in Patients with Infection Presenting to the Emergency Department: A Pilot Study
Journal of Personalized Medicine · 11.06.2026 · 16 (6) · 312
DOI: 10.3390/jpm16060312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 11.06.2026. Verfasst von Louiza Mpoumi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, 12462 Athens, Greece. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Pancreatic stone protein (PSP) has recently emerged as a novel biomarker with diagnostic and prognostic potential in sepsis. The present study aimed to investigate its role as an early prognosticator in patients presenting to the Emergency Department (ED) with various types of infection.
Methods
Point-of-care PSP was measured in 102 consecutive patients (59.8% male) with mean age of 62.7 (±23.4) years, presenting to the ED with suspected or confirmed infection. We examined the utility of PSP to predict adverse events including death, development of septic shock or need for repeated medical evaluation due to persistence or worsening of initial symptoms during a 10-day follow-up period.
Results
Respiratory tract infections were the most common (50%) followed by urinary tract infections (17.6%), sepsis of unknown origin (4.9%) and other infections (27.5%). PSP exhibited intermediate performance in predicting short-term adverse outcomes with an AUC of 0.734 (p < 0.001). In contrast, other inflammatory biomarkers such as procalcitonin, C-reactive protein (CRP) and White Blood Cells (WBCs) did not predict adverse outcomes (procalcitonin: AUC 0.680, p = 0.059; CRP: AUC 0.593, p = 0.072; WBC: AUC 0.635, p = 0.074).
Conclusions
PSP appears to be a promising biomarker reflecting the severity of infection. Point-of-care PSP evaluation may serve as an early predictor of adverse events in patients presenting with infection to the ED.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, 12462 Athens, Greece.
- 4th Department of Internal Medicine, Attikon University Hospital, Rimini 1, 12462 Athens, Greece.
ORCID-Profile: Vasiliki Bistola, Sofia Bezati, Christos Verras, Sotirios Tsiodras, Effie Polyzogopoulou
Zitieren
APA
Mpoumi, L., Sarantos, G., Bistola, V., Bezati, S., Verras, C., Rita, I., Tsiodras, S., Parissis, J., & Polyzogopoulou, E. (2026). Pancreatic Stone Protein as an Early Predictor of Adverse Events in Patients with Infection Presenting to the Emergency Department: A Pilot Study. Journal of Personalized Medicine, 16(6), 312. https://doi.org/10.3390/jpm16060312
Vancouver
Mpoumi L, Sarantos G, Bistola V, Bezati S, Verras C, Rita I, et al. Pancreatic Stone Protein as an Early Predictor of Adverse Events in Patients with Infection Presenting to the Emergency Department: A Pilot Study. Journal of Personalized Medicine. 2026;16(6):312. doi:10.3390/jpm16060312
BibTeX
@article{Mpoumi2026,
author = {Mpoumi, Louiza and Sarantos, Georgia and Bistola, Vasiliki and Bezati, Sofia and Verras, Christos and Rita, Ioanna and Tsiodras, Sotirios and Parissis, John and Polyzogopoulou, Effie},
title = {Pancreatic Stone Protein as an Early Predictor of Adverse Events in Patients with Infection Presenting to the Emergency Department: A Pilot Study},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {6},
pages = {312},
doi = {10.3390/jpm16060312}
}
EUVIMED